Protein biomarker indicators of neurological injury and/or disease and methods of use thereof

A method of assessing whether a therapy or treatment regimen for a neurological injury or brain injury is effective in a subject, the method comprising:

• (A) quantitatively measuring the levels of the one or more protein biomarkers, or fragments thereof, in a biological sample obtained from a subject at a first time point prior to initiation of a therapy or treatment regimen for a neurological or brain injury, wherein the one or more protein biomarkers or fragments thereof, are selected from the group consisting of a synaptogenesis protein, an innate immunity protein, a metabolism protein, an inflammation protein, and a vascular damage protein;
• (B) quantitatively measuring the levels of the same, one or more protein biomarkers, or fragments thereof, in step (A), in a biological sample obtained from the subject at a second time point, after initiation of the therapy or treatment regimen;
• and
• (C) (i) ceasing treatment for neurological injury or brain injury when the measured levels of the one or more protein biomarkers, or fragments thereof, are decreased or trending to normal levels, in the biological sample obtained at the second time point, as compared with measured levels of the one or more protein biomarkers, or fragments thereof, at the first time point;
• or
• (ii) continuing treatment for neurological injury or brain injury when the measured levels of the one or more protein biomarkers, or fragments thereof, are increased or trending to abnormal levels, in the biological sample obtained at the second time point, as compared with measured levels of the one or more protein biomarkers, or fragments thereof, at the first time point.